Compare Repligen Corporation Common Stock (RGEN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Veritone Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Veritone Inc trades at $0.53 (market cap $59.95M). The key difference: Repligen Corporation Common Stock is far larger — about 185.8× Veritone Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Veritone Inc for 13 Days on average.
| RGEN | VERI | |
|---|---|---|
Market Cap | $11.14B | $59.95M |
Volume | 1,259,263 | 2,880,267 |
Sector | Health | Technology |
52-Week High | $194.57 | $8.39 |
52-Week Low | $102.87 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $11.02B | $95.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Veritone (VERI) trades at $0.59, down 2.64% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative cash flow from operations. Recent news includes a $15M equity offering and partnerships like the ATP Media deal, while facing a securities class action investigation.
The outlook remains challenged by persistent losses and cash burn, though analyst consensus is a Buy with a $3.75 price target. Key risks include execution on cost reductions, competitive pressures in AI, and legal overhangs. Upside hinges on revenue acceleration and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
